1
|
Salama A, Mosser M, Lévêque X, Perota A, Judor JP, Danna C, Pogu S, Mouré A, Jégou D, Gaide N, Abadie J, Gauthier O, Concordet JP, Le Bas-Bernardet S, Riochet D, Le Berre L, Hervouet J, Minault D, Weiss P, Guicheux J, Brouard S, Bosch S, Lagutina I, Duchi R, Lazzari G, Cozzi E, Blancho G, Conchon S, Galli C, Soulillou JP, Bach JM. Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs. Diabetes 2017; 66:987-993. [PMID: 28082457 DOI: 10.2337/db16-1060] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Accepted: 01/08/2017] [Indexed: 11/13/2022]
Abstract
Xenocell therapy from neonate or adult pig pancreatic islets is one of the most promising alternatives to allograft in type 1 diabetes for addressing organ shortage. In humans, however, natural and elicited antibodies specific for pig xenoantigens, α-(1,3)-galactose (GAL) and N-glycolylneuraminic acid (Neu5Gc), are likely to significantly contribute to xenoislet rejection. We obtained double-knockout (DKO) pigs lacking GAL and Neu5Gc. Because Neu5Gc-/- mice exhibit glycemic dysregulations and pancreatic β-cell dysfunctions, we evaluated islet function and glucose metabolism regulation in DKO pigs. Isolation of islets from neonate piglets yielded identical islet equivalent quantities to quantities obtained from control wild-type pigs. In contrast to wild-type islets, DKO islets did not induce anti-Neu5Gc antibody when grafted in cytidine monophosphate-N-acetylneuraminic acid hydroxylase KO mice and exhibited in vitro normal insulin secretion stimulated by glucose and theophylline. Adult DKO pancreata showed no histological abnormalities, and immunostaining of insulin and glucagon was similar to that from wild-type pancreata. Blood glucose, insulin, C-peptide, the insulin-to-glucagon ratio, and HOMA-insulin resistance in fasted adult DKO pigs and blood glucose and C-peptide changes after intravenous glucose or insulin administration were similar to wild-type pigs. This first evaluation of glucose homeostasis in DKO pigs for two major xenoantigens paves the way to their use in (pre)clinical studies.
Collapse
Affiliation(s)
- Apolline Salama
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
- Société d'Accélération du Transfert de Technologies Ouest Valorisation, Rennes, France
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Mathilde Mosser
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Xavier Lévêque
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Andrea Perota
- Avantea Laboratory of Reproductive Technologies, Cremona, Italy
| | - Jean-Paul Judor
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Corentin Danna
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Sylvie Pogu
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Anne Mouré
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Dominique Jégou
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Nicolas Gaide
- Animal cancers as Models for Research in comparative Oncology (AMaROC), Oniris, Nantes, France
| | - Jérôme Abadie
- Animal cancers as Models for Research in comparative Oncology (AMaROC), Oniris, Nantes, France
| | - Olivier Gauthier
- Department of Experimental Surgery, Center for Research and Preclinical Investigation, Oniris, Nantes, France
| | - Jean-Paul Concordet
- Muséum National d'Histoire Naturelle, Paris, France
- CNRS UMR 7196, Paris, France
- INSERM U1154, Paris, France
| | - Stéphanie Le Bas-Bernardet
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - David Riochet
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
- Department of Pediatrics, Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Ludmilla Le Berre
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Jérémy Hervouet
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - David Minault
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Pierre Weiss
- INSERM UMRS 791, Laboratoire d'ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Nantes, France; University of Nantes, UFR Odontologie, Nantes, France
- Nantes University Hospital-CHU de Nantes, PHU4 OTONN, Nantes, France
| | - Jérôme Guicheux
- INSERM UMRS 791, Laboratoire d'ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Nantes, France; University of Nantes, UFR Odontologie, Nantes, France
- Nantes University Hospital-CHU de Nantes, PHU4 OTONN, Nantes, France
| | - Sophie Brouard
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
- Centre d'investigation clinique (CIC) Biotherapy, Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Steffi Bosch
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| | - Irina Lagutina
- Avantea Laboratory of Reproductive Technologies, Cremona, Italy
| | - Roberto Duchi
- Avantea Laboratory of Reproductive Technologies, Cremona, Italy
| | - Giovanna Lazzari
- Avantea Laboratory of Reproductive Technologies, Cremona, Italy
- Avantea Foundation, Cremona, Italy
| | - Emanuele Cozzi
- Transplantation Immunology Unit, Department of Transfusion Medicine, University of Padua-Ospedale Giustinianeo, Padua, Italy
- CORIT (Consortium for Research in Organ Transplantation), Padua, Italy
| | - Gilles Blancho
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
- Centre d'investigation clinique (CIC) Biotherapy, Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Sophie Conchon
- INSERM CRTI UMR 1064, University of Nantes, Nantes, France
- Institute of Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital-CHU de Nantes, Nantes, France
| | - Cesare Galli
- Avantea Laboratory of Reproductive Technologies, Cremona, Italy
- Avantea Foundation, Cremona, Italy
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano Emilia, Italy
| | | | - Jean-Marie Bach
- IECM, Immuno-endocrinology, EA4644 Oniris, University of Nantes, USC1383 INRA, Oniris, Nantes, France
| |
Collapse
|
3
|
Fink KD, Crane AT, Lévêque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE, Antcliff A, Starski PA, Lu M, Lescaudron L, Rossignol J, Dunbar GL. Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. Stem Cells Transl Med 2014; 3:620-31. [PMID: 24657963 DOI: 10.5966/sctm.2013-0151] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Induced pluripotent stem cells (iPSCs) show considerable promise for cell replacement therapies for Huntington's disease (HD). Our laboratory has demonstrated that tail-tip fibroblasts, reprogrammed into iPSCs via two adenoviruses, can survive and differentiate into neuronal lineages following transplantation into healthy adult rats. However, the ability of these cells to survive, differentiate, and restore function in a damaged brain is unknown. To this end, adult rats received a regimen of 3-nitropropionic acid (3-NP) to induce behavioral and neuropathological deficits that resemble HD. At 7, 21, and 42 days after the initiation of 3-NP or vehicle, the rats received intrastriatal bilateral transplantation of iPSCs. All rats that received 3-NP and vehicle treatment displayed significant motor impairment, whereas those that received iPSC transplantation after 3-NP treatment had preserved motor function. Histological analysis of the brains of these rats revealed significant decreases in optical densitometric measures in the striatum, lateral ventricle enlargement, as well as an increase in striosome size in all rats receiving 3-NP when compared with sham rats. The 3-NP-treated rats given transplants of iPSCs in the 7- or 21-day groups did not exhibit these deficits. Transplantation of iPSCs at the late-stage (42-day) time point did not protect against the 3-NP-induced neuropathology, despite preserving motor function. Transplanted iPSCs were found to survive and differentiate into region-specific neurons in the striatum of 3-NP rats, at all transplantation time points. Taken together, these results suggest that transplantation of adenovirus-generated iPSCs may provide a potential avenue for therapeutic treatment of HD.
Collapse
Affiliation(s)
- Kyle D Fink
- Field Neurosciences Institute Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, and College of Medicine, Central Michigan University, Mount Pleasant, Michigan, USA; Faculté des Sciences et des Techniques, Faculté de Médecine, and Faculté d'Odontologie, Université de Nantes, Nantes, France; INSERM U1064, ITUN, Nantes, France; INSERM U791, Laboratoire d'Ingenierie Osteo-Articulaire et Dentaire, Nantes, France; INSERM UMR 643, Nantes, France; Field Neurosciences Institute, Saginaw, Michigan, USA; Centre Hospitalier-Universitaire Hotel Dieu de Nantes, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Fink KD, Rossignol J, Lu M, Lévêque X, Hulse TD, Crane AT, Nerriere-Daguin V, Wyse RD, Starski PA, Schloop MT, Dues DJ, Witte SJ, Song C, Vallier L, Nguyen TH, Naveilhan P, Anegon I, Lescaudron L, Dunbar GL. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. Cell Transplant 2013; 23:1407-23. [PMID: 23879897 DOI: 10.3727/096368913x670958] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Induced pluripotent stem cells (iPSCs) offer certain advantages over embryonic stem cells in cell replacement therapy for a variety of neurological disorders. However, reliable procedures, whereby transplanted iPSCs can survive and differentiate into functional neurons, without forming tumors, have yet to be devised. Currently, retroviral or lentiviral reprogramming methods are often used to reprogram somatic cells. Although the use of these viruses has proven to be effective, formation of tumors often results following in vivo transplantation, possibly due to the integration of the reprogramming genes. The goal of the current study was to develop a new approach, using an adenovirus for reprogramming cells, characterize the iPSCs in vitro, and test their safety, survivability, and ability to differentiate into region-appropriate neurons following transplantation into the rat brain. To this end, iPSCs were derived from bone marrow-derived mesenchymal stem cells and tail-tip fibroblasts using a single cassette lentivirus or a combination of adenoviruses. The reprogramming efficiency and levels of pluripotency were compared using immunocytochemistry, flow cytometry, and real-time polymerase chain reaction. Our data indicate that adenovirus-generated iPSCs from tail-tip fibroblasts are as efficient as the method we used for lentiviral reprogramming. All generated iPSCs were also capable of differentiating into neuronal-like cells in vitro. To test the in vivo survivability and the ability to differentiate into region-specific neurons in the absence of tumor formation, 400,000 of the iPSCs derived from tail-tip fibroblasts that were transfected with the adenovirus pair were transplanted into the striatum of adult, immune-competent rats. We observed that these iPSCs produced region-specific neuronal phenotypes, in the absence of tumor formation, at 90 days posttransplantation. These results suggest that adenovirus-generated iPSCs may provide a safe and viable means for neuronal replacement therapies.
Collapse
Affiliation(s)
- Kyle D Fink
- Program in Neuroscience, Field Neurosciences Laboratory for Restorative Neurology Brain Research and Integrative Neuroscience Center, Central Michigan University, Mount Pleasant, MI, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|